Monday , April 24 2017
Home / 2017 / April

Monthly Archives: April 2017

Gilead Announces Positive Proof-of-Concept Data for its NASH Candidate

FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq:GILD) today announced results from an open-label, proof-of-concept study evaluating GS-0976, an investigational inhibitor of Acetyl-CoA carboxylase (ACC), in patients with nonalcoholic steatohepatitis (NASH). The data, from ten patients treated with GS-0976 20 mg taken orally once daily for 12 weeks, indicated that treatment …

Read More »

New Study Reveals Payers and Hospitals Can Save Millions in Readmission Costs, Hospitalization Rates for COPD Patients

AMSTERDAM, April 21, 2017 /PRNewswire/ — Royal Philips (NYSE: PHG, AEX: PHIA) today announced results1 from a recent study showing significant decreases in both hospital and payer costs and hospitalization rates for severe chronic obstructive pulmonary disease (COPD)2 patients. The study entitled, “Cost Savings from Reduced Hospitalizations with Use of …

Read More »

AbbVie’s Pan-Genotypic HCV Regimen Achieves a 99% Cure Rate in Late-Stage Study

AMSTERDAM, April 20, 2017 /PRNewswire/ — AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that 99 percent (n=145/146) of chronic hepatitis C virus (HCV) infected patients with genotype 1, 2, 4, 5 or 6 and compensated cirrhosis (Child-Pugh A) achieved sustained virologic response at 12 weeks post-treatment (SVR12) with its …

Read More »

H3 Biomedicine Extends Collaboration with Foundation Medicine to Develop Precision Therapies for Cancer

CAMBRIDGE, Mass.–(BUSINESS WIRE)–H3 Biomedicine Inc., a clinical stage biopharmaceutical company specializing in the discovery and development of precision medicines for oncology and a member of Eisai’s global Oncology Business Group, today announced that is has extended its multi-year collaboration with Foundation Medicine, Inc. for the discovery and development of precision …

Read More »

Valeant Prices Injectable Psoriasis Drug Siliq at $3,500 Per Month

LAVAL, Quebec, April 21, 2017 /PRNewswire/ — Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that following the evaluation and approval of its Patient Access and Pricing Committee (PAPC), the company has decided to list SILIQ™ (brodalumab) injection, at $3,500 per month, which is the lowest injectable …

Read More »

AbbVie’s PARP Inhibitor Fails Two Late-Stage Cancer Trials

NORTH CHICAGO, Ill., April 19, 2017 /PRNewswire/ — AbbVie, a global biopharmaceutical company, today announced that two Phase 3 studies evaluating veliparib, an investigational, oral poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor did not meet their primary endpoints. The studies evaluated veliparib in combination with the chemotherapy regimen carboplatin and …

Read More »

Novartis Enters Deal to Use Parvus’ Navacim Technology to Develop and Commercialize Type 1 Diabetes Drugs

CALGARY, Alberta–(BUSINESS WIRE)–Parvus Therapeutics, a biopharmaceutical company developing disease-modifying nanomedicines to halt or reverse autoimmune disease without causing general immune suppression, has entered into a license and collaboration agreement with Novartis for its lead Navacim for treating type 1 diabetes. Navacims constitute a novel pharmacological class of therapeutic comprised of …

Read More »

FDA Grants Breakthrough Therapy and Regenerative Advanced Therapy Designation to Enzyvant’s RVT-802

BASEL, Switzerland, April 17, 2017 /PRNewswire/ — Enzyvant, a biopharmaceutical company focused on developing innovative treatments for patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted RVT-802, Enzyvant’s investigational tissue-based therapy for the treatment of complete DiGeorge Syndrome (cDGS), Breakthrough Therapy designation as …

Read More »

Ultragenyx Announces Positive Late-Stage Results for its X-Linked Hypophosphatemia Drug

NOVATO, Calif., LONDON and TOKYO, April 18, 2017 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin) and Kyowa Kirin International PLC, a wholly owned subsidiary of Kyowa Hakko Kirin, today announced positive 24-week data from the randomized, double-blind, placebo-controlled Phase 3 study of …

Read More »

Novartis’ CAR-T Therapy Receives Breakthrough Therapy Designation for Diffuse Large B-Cell Lymphoma

Basel, April 18, 2017 – Novartis announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to CTL019, an investigational chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of adult patients with relapsed and refractory (r/r) diffuse large B-cell lymphoma (DLBCL), who have …

Read More »